Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 439 |
| Active Pipeline (Recruiting Now) | 201 (101) |
| Completed vs Stopped Early | 195 / 43 (9.8%) |
| Median Closed Actual Enrollment | 302 participants |
| Physical Hospital Site Disclosure | 99.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 183 (15 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 68 |
| University of Colorado Anschutz Medical Campus | Aurora, CO | 55 |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | 53 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer | Phase III | RECRUITING |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase III | RECRUITING |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in | Phase III | RECRUITING |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participan | Phase III | RECRUITING |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Merck & Co. Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.